Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 12/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.47 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.33 |
| ▸ | CHRNG | P07510 | 1/20 | 0.33 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | CHRND | Q07001 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15043705 | 0.83 | SLC6A4 (0.50) | SLC6A4SLC6A3SLC6A2CCR2DPP4 | |
| SCHEMBL12000529 | 0.81 | SLC6A4 (0.50) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL15042371 | 0.81 | SLC6A4 (0.54) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL15042374 | 0.81 | SLC6A4 (0.44) | SLC6A4SLC6A3SLC6A2CCR2CHRNA1 | |
| SCHEMBL3521865 | 0.76 | SLC6A4 (0.53) | SLC6A4SLC6A3SLC6A2CCR2DPP4 | |
| SCHEMBL15862757 | 0.74 | SLC6A4 (0.50) | SLC6A4SLC6A3SLC6A2CCR2DPP4 | |
| SCHEMBL28804064 | 0.74 | SLC6A3 (0.46) | SLC6A4SLC6A3SLC6A2CCR2DPP4 | |
| SCHEMBL10179262 | 0.72 | SLC6A3 (0.41) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL15042438 | 0.72 | SLC6A4 (0.33) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL13107026 | 0.71 | SLC6A4 (0.46) | SLC6A4SLC6A3SLC6A2CCR2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822510-B2 | Substituted 3-phenyl-1,2,4-Oxadiazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130158001-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | BRISTOL-MYERS SQUBIB COMPANY | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158001-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | S1PR1, S1PR3, S1PR2 | SLC6A4 2698/4885SLC6A3 2766/4885SLC6A2 2889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.